Clinical Trial Update: Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating whether adding low-dose lenalidomide to ixazomib maintenance improves outcomes for high-risk multiple myeloma compared wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Ixazomib (Ninlaro) (Ixazomib)
• Lenalidomide (Revlimid) (lenalidomide)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Multiple Myeloma | Phase 4 | Status: RECRUITING